SOPHiA GENETICS and The University of Texas MD Anderson Cancer Center have announced a strategic collaboration aimed at accelerating AI-driven precision oncology by combining advanced analytics with leading clinical and scientific expertise.
Under the partnership, SOPHiA GENETICS will integrate its AI-powered analytics platform, SOPHiA DDM™, with MD Anderson’s oncology research and clinical capabilities to develop new tools that can more accurately analyse, interpret, and translate complex diagnostic data into clinical practice. The collaboration focuses on addressing the growing challenge clinicians face as cancer research becomes increasingly data-intensive.
A central component of the partnership is the co-development of an advanced next-generation sequencing (NGS) oncology test built on SOPHiA DDM™’s AI algorithms. The test is designed to transform high-dimensional, multimodal genomic and molecular data into actionable clinical insights with greater speed and scalability. MD Anderson researchers will leverage SOPHiA GENETICS’ AI technologies to build bioinformatics pipelines capable of rapidly interpreting complex RNA-sequencing data, supporting more informed diagnosis and treatment decisions for patients with cancer.
Beyond test development, the two organisations will jointly launch a series of research and development programmes focused on characterising tumour evolution in real time, strengthening the reliability and reproducibility of advanced genomic testing, and improving the identification of optimal clinical trials or research pathways for individual patients. These initiatives are intended to deepen understanding of cancer’s dynamic nature while equipping clinicians and researchers with tools to support next-generation discovery.
The collaboration also aims to extend the reach of MD Anderson’s clinical and research innovations beyond its own institution. By enabling hospitals and research centres globally to benefit from insights generated within MD Anderson’s research environment, the partnership seeks to broaden access to precision oncology advances worldwide. At the same time, it is structured around a decentralised and collaborative AI ecosystem that allows participating institutions to retain full ownership of their data.
The joint work at MD Anderson will be led by Shashikant Kulkarni, PhD, Deputy Division Head for Molecular Pathology, and J. Bryan, MD, Assistant Professor, both within the Division of Pathology and Laboratory Medicine. On the SOPHiA GENETICS side, the collaboration is being driven by senior leadership including Co-Founder and CEO Dr Jurgi Camblong, Chief Product Officer and Chief Medical Officer Philippe Menu, and President Ross Muken.
Together, SOPHiA GENETICS and MD Anderson aim to accelerate data-driven cancer care, advance precision oncology research, and support the translation of complex genomic insights into real-world clinical impact at global scale.
